Takeda Pharma Files 6-K, Confirms 20-F Reporting

TL;DR

Takeda filed a 6-K on 10/31/24, confirming it's a foreign private issuer using Form 20-F for annual reports. No new info.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on October 31, 2024, reporting its status as a foreign private issuer. The filing indicates that Takeda will file its annual reports under Form 20-F. No specific financial figures or operational updates were detailed in this particular filing.

Why It Matters

This filing is a routine procedural update for foreign private issuers, confirming their reporting framework with the SEC and does not contain new operational or financial information.

Risk Assessment

Risk Level: low — This is a standard procedural filing by a foreign private issuer and does not contain new material information that would typically impact stock price.

Key Players & Entities

• Takeda Pharmaceutical Company Limited (company) — Filer
• 20241031 (date) — Filing Date
• Form 6-K (document) — Filing Type
• Form 20-F (document) — Annual Report Form

FAQ

Filing Documents

• form6k-2_103124.htm (6-K) — 60KB
• 0001395064-24-000163.txt ( ) — 61KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date October 31, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS) OSAKA, Japan, October 31, 2024 – Takeda (TSE4502NYSETAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below. 1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2025 (millions JPY) Revenue Operating profit Profit before income taxes Net profit attributable to owners of the Company Basic earnings per share Original Forecast (A) * 4,350,000 225,000 55,000 58,000 36.70 JPY Revised Forecast (B) 4,480,000 265,000 93,000 68,000 43.03 JPY Discrepancy (B-A) 130,000 40,000 38,000 10,000 Change % 3.0% 17.8% 69.1% 17.2% * Announced on May 9, 2024. (millions JPY) Core Revenue Core Operating Profit Core EPS Original Forecast (A) * 4,350,000 1,000,000 431 JPY Revised Forecast (B) 4,480,000 1,050,000 456 JPY Discrepancy (B-A) 130,000 50,000 Change % 3.0% 5.0% * Announced on May 9, 2024. (Note) For the definition of Core financial measures, please refer to the "Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations" in the Financial Appendix attached to the Earnings Report. 2. Reasons for Revision Takeda expects FY2024 revenue to be JPY 4,480.0 billion, an increase of JPY 130.0 billion, or 3.0%, from the original forecast. This is primarily attributable to milder than anticipated generic erosion of VYVANSE after the loss of exclusivity in the U.S. and other business momentum as well as favorable overall changes

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States competitive pressures and developments changes to applicable laws and regulations challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits and other factors ident

View Full Filing

View this 6-K filing on SEC EDGAR